| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2917 | Khg26693 | Novel anti-inflammatory and antioxidant agent, significantly decreasing blood glucose, triglycerides, and cholesterol and increased insulin |
|
| DCC2918 | Ki23057 | Novel FGFR2 inhibitor, enhancing the chemosensitivity of drug-resistant gastric cancer cell lines |
|
| DCC2919 | Kif18a Inhibitor 23 | Novel KIF18A inhibitor, causing significant mitotic arrest in vivo, binding at the interface of KIF18A and tubulin |
|
| DCC2920 | Ki-ms2-008 | Novel Max-binding modulator, attenuating Myc-driven transcription and stabilizing the Max homodimer |
|
| DCC2921 | kin100 | Novel inducer of the ISG54 promoter, causing IRF-3 translocation |
|
| DCC2922 | Kir1.1-in-a | Novel potent and selective inhibitor of kir1.1 channels |
|
| DCC2923 | Kist301072 | Novel ROS1 kinase inhibitor |
|
| DCC2924 | Kist301080 | Novel ROS1 kinase inhibitor |
|
| DCC2925 | Kjm429 | Novel TRPV1 antagonist |
|
| DCC2926 | Kj-pyr-10 | Novel specific inhibitor of MYC |
|
| DCC2927 | Kkha-761 | Potent D3 receptor antagonist with high 5-HT1A receptor affinity |
|
| DCC2928 | Kl-1156 | Novel NF-κB inhibitor and lipopolysaccharide (LPS)-induced nitric oxide production inhibitor |
|
| DCC2929 | Kld-12 | Self-assembling peptide, forming a hydrogel matrix to support growth of cells in the presence of an ionic solution, enhancing chondrogenic differentiation of bone marrow stromal cells (BMSCs) |
|
| DCC2930 | Klebsazolicin | Novel inhibitor of 70S ribosome by obstructing the peptide exit tunnel |
|
| DCC2931 | Klk6-in-32 | First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro |
|
| DCC2932 | Klk6-in-42 | First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro |
|
| DCC2933 | Kl-l9p | Novel antibiotic sensitizer, promoting the rearrangement of the bacterial membrane that enables hydrophobic antibiotics to permeate, strongly sensitizing Gram-negative bacteria to linezolid (Lzd), rifampicin (Rif), or clarithromycin (Clr) |
|
| DCC2934 | Boc-phe-leu-glup(oph) | 0 |
|
| DCC2935 | Km05382 | CDK9 inhibitor, inhibiting transcription of GAPDH |
|
| DCC2936 | km10340 | Selective S1P3 agonist |
|
| DCC2937 | Km-5-25 | Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe |
|
| DCC2938 | Km-5-66 | Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe |
|
| DCC2939 | kmi-1764 | Novel BACE1 inhibitor with a non-acidic heterocycle at the P1' position |
|
| DCC2940 | Kmn-010034 | Novel Potent Hematopoietic Prostaglandin D2 Synthase (H-PGDS) Inhibitor |
|
| DCC2941 | Kmn-80 | Novel Potent and Selective EP4 Agonist |
|
| DCC2942 | kms80013 | Novel inhibitor of amyloid- |
|
| DCC2943 | Kms88009 | Novel inhibitor of amyloid-β aggregation, ameliorating the neurodegenerative disorder |
|
| DCC2944 | Kmup-3 | Novel enhancer of cGMP activity; Aortic smooth muscle relaxant |
|
| DCC2945 | Kmup-4 | Novel enhancer of cGMP activity; Aortic smooth muscle relaxant |
|
| DCC2946 | Kongensin D | Natural anti-TNBC agent, significantly suppressing the triple-negative breast cancer (TNBC) tumor growth without causing side effects |
|
